United Therapeutics chairperson & CEO sells $5.19m in stock
United Therapeutics' chair and CEO, Martine A. Rothblatt, sold approximately $5.19 million worth of company stock on October 15, 2026, according to a recent filing. The sale, which comprised 9,500 shares, was executed under a pre-established trading plan and followed the exercise of stock options for an equal amount of shares. The transactions occurred at prices ranging from $540.4764 to $551.5 per share.
United Therapeutics, valued at $23.2 billion, has seen a 23% return over the past year, but the stock's current price suggests it may be overvalued. Despite this insider sale, the company continues to buy back shares, showing confidence in its future. The company's financial health remains strong, with a high rating and a reasonable P/E ratio of 19.1.
Rothblatt, who indirectly holds 324,443 shares and 223,910 derivative securities, disclosed these transactions through a Rule 10b5-1 plan, set to continue until December 31, 2026.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- PTC Therapeutics director sells $149,036 in shares investing.com
